Retatrutide - 20mg

RT-20 | 20 mg Retatrutide vial – add bacteriostatic water.

Retatrutide (LY3437943): The Advanced Triple Agonist for Metabolic Health Research

Overview

Retatrutide, developed by Eli Lilly, represents the next evolution in peptide-based metabolic therapy research. As a triple-receptor agonist, Retatrutide activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors — offering a broader and more balanced metabolic response than single or dual agonists such as semaglutide and tirzepatide.

This multifaceted mechanism enables simultaneous insulin-sensitising, fat-mobilising, and energy-expenditure-enhancing activity, making Retatrutide a major focus of ongoing research into obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).

Key Research Insights & Potential Advantages

• Significant Weight Reduction
• Retatrutide promotes marked reductions in body mass through enhanced lipolysis, fat oxidation, and thermogenesis, with participants in Phase 2 trials showing up to 24.2 % average weight loss over 48 weeks.
• Enhanced Satiety and Appetite Regulation
• By modulating hypothalamic pathways and delaying gastric emptying, Retatrutide reduces appetite and prolongs fullness, contributing to sustained caloric control.
• Improved Glycaemic Management
• Stimulates glucose-dependent insulin secretion, suppresses glucagon, and improves HbA1c levels — demonstrating superior glycaemic outcomes compared with single-pathway agonists.
• Comprehensive Metabolic Improvements
• Research indicates positive effects on lipid profiles, insulin sensitivity, and hepatic fat content, positioning Retatrutide as a promising investigational agent in metabolic disorder studies.

Retatrutide vs. Semaglutide and Tirzepatide

The inclusion of glucagon receptor activation allows Retatrutide to couple catabolic fat-burning effects with anabolic glucose regulation, offering a more complete metabolic profile.

Emerging Areas of Research

Preliminary data suggest potential applications in studies involving polycystic ovary syndrome (PCOS), metabolic liver disease, and cardiometabolic dysfunction, pending further clinical validation.

For Research Use in Australia

Retatrutide (LY3437943) is supplied for laboratory and research purposes only and is not intended for human consumption or therapeutic use. Australian researchers and clinicians exploring metabolic peptide mechanisms regard Retatrutide as a leading candidate for next-generation metabolic health investigations.